Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304561 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9304569 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16671458 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8621737 | 0.86 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8623413 | 0.86 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9128197 | 0.86 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8621731 | 0.86 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8623417 | 0.86 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL21631695 | 0.86 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL21631709 | 0.86 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758500-B2 | Process for the preparation of (3E, 7E)-homofarnesol | BASF SE (DE) | 2017-09-12 | — | — | US | disclosed |
| US-9758500-B2 | Process for the preparation of (3E, 7E)-homofarnesol | BASF SE (DE) | 2017-09-12 | — | — | US | disclosed |
| US-20170029396-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | BASF SE (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029396-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | BASF SE (DE) | 2017-02-02 | — | — | US | disclosed |
| US-9493385-B2 | Process for the preparation of (3E, 7E)-homofarnesol | BASF SE (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9493385-B2 | Process for the preparation of (3E, 7E)-homofarnesol | BASF SE (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160200648-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | BASF SE (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200648-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | BASF SE (DE) | 2016-07-14 | — | — | US | disclosed |
| WO-2013156398-A1 | IMPROVED PROCESS FOR PREPARING (3E,7E)-HOMOFARNESOL | BASF SE (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130273619-A1 | Process for the Preparation of (3E, 7E)-Homofarnesol | BASF SE (DE) | 2013-10-17 | — | — | US | disclosed |
| US-20130273619-A1 | Process for the Preparation of (3E, 7E)-Homofarnesol | BASF SE (DE) | 2013-10-17 | — | — | US | disclosed |
| EP-2452679-A1 | CYTOPROTECTIVE AGENT | National University Corporation Tokyo University Of Agriculture and Technology (JP) | 2012-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200648-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | CYP8B1, CYP4F3, CYP2J2 | KMT2A 3917/4885MAPT 4761/4885MEN1 4239/4885 |
| US-20170029396-A1 | PROCESS FOR THE PREPARATION OF (3E, 7E)-HOMOFARNESOL | CYP8B1, CYP4F3, CYP2J2 | KMT2A 3917/4885MAPT 4761/4885MEN1 4239/4885 |
| US-20130273619-A1 | Process for the Preparation of (3E, 7E)-Homofarnesol | CYP8B1, CYP4F3, CYP2J2 | KMT2A 3917/4885MAPT 4761/4885MEN1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.